[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP6485783B2 - Medical inspection apparatus and cell inspection method - Google Patents

Medical inspection apparatus and cell inspection method Download PDF

Info

Publication number
JP6485783B2
JP6485783B2 JP2017144556A JP2017144556A JP6485783B2 JP 6485783 B2 JP6485783 B2 JP 6485783B2 JP 2017144556 A JP2017144556 A JP 2017144556A JP 2017144556 A JP2017144556 A JP 2017144556A JP 6485783 B2 JP6485783 B2 JP 6485783B2
Authority
JP
Japan
Prior art keywords
hydrophilic polymer
polymer layer
blood
adsorbed
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017144556A
Other languages
Japanese (ja)
Other versions
JP2018059901A (en
Inventor
皆川 康久
康久 皆川
賢 田中
賢 田中
隆志 干場
隆志 干場
智和 渋谷
智和 渋谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Rubber Industries Ltd
Yamagata University NUC
Original Assignee
Sumitomo Rubber Industries Ltd
Yamagata University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Rubber Industries Ltd, Yamagata University NUC filed Critical Sumitomo Rubber Industries Ltd
Priority to US15/693,919 priority Critical patent/US10941374B2/en
Priority to EP17189342.3A priority patent/EP3301443B1/en
Priority to CN201710826823.3A priority patent/CN107884558B/en
Publication of JP2018059901A publication Critical patent/JP2018059901A/en
Application granted granted Critical
Publication of JP6485783B2 publication Critical patent/JP6485783B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Sampling And Sample Adjustment (AREA)
  • Coating Of Shaped Articles Made Of Macromolecular Substances (AREA)

Description

本発明は、血液及び体液中の特定の細胞(血液・体液中に存在するがん細胞等)を捕捉できる医療用検査装置及び細胞検査方法に関する。 The present invention relates to a medical test apparatus and a cell test method capable of capturing specific cells in blood and body fluids (such as cancer cells present in blood and body fluids).

がん細胞が発生するとやがて、血液・体液中に出て来ることが知られており、血液中に出て来たがん細胞は、血中循環腫瘍細胞(CTC)と呼ばれている。そして、この血中循環腫瘍細胞を調べることによるがんの治療効果の確認、予後寿命、投与前の抗がん剤の効果予測、がん細胞の遺伝子解析を用いた治療方法の検討、等が期待されている。 It is known that cancer cells will eventually come out in the blood and body fluids, and the cancer cells that have come out in the blood are called circulating tumor cells (CTC). Confirmation of cancer treatment effects by examining circulating tumor cells in the blood, prognostic life span, prediction of anticancer drug effects before administration, examination of treatment methods using genetic analysis of cancer cells, etc. Expected.

しかしながら、血中循環腫瘍細胞は非常に数が少なく(数個〜数百個/血液1mL)、がん細胞を捕捉することが難しいという問題がある。 However, there are problems that circulating tumor cells in blood are very few (several to several hundreds / 1 mL of blood) and it is difficult to capture cancer cells.

例えば、血中循環腫瘍細胞の捕捉技術として、Cell Searchシステムと呼ばれるものが知られているが、これは、抗原抗体反応(EpCAM抗体で捕捉)を用いる技術であるため、EpCAMを発現しているがん細胞しか捕捉できず、補足可能ながん細胞の種類に制限がある。 For example, a technique called the Cell Search system is known as a technique for capturing circulating tumor cells in the blood. This technique uses an antigen-antibody reaction (captured with an EpCAM antibody), and thus expresses EpCAM. Only cancer cells can be captured, and the types of cancer cells that can be captured are limited.

特表2005−523981号公報Japanese translation of PCT publication No. 2005-523981

本発明は、前記課題を解決し、EpCAMを発現していないがん細胞も含め、多くのがん細胞を捕捉できる医療用検査装置及び細胞検査方法を提供することを目的とする。 An object of the present invention is to solve the above-mentioned problems and to provide a medical test apparatus and a cell test method capable of capturing many cancer cells including cancer cells that do not express EpCAM.

本発明は、ウェル部を有する医療用検査装置であって、前記ウェル部の内面の少なくとも一部に親水性ポリマー層が形成され、かつ前記親水性ポリマー層にフィブロネクチンが吸着されている医療用検査装置に関する。 The present invention is a medical examination apparatus having a well portion, wherein a hydrophilic polymer layer is formed on at least a part of the inner surface of the well portion, and fibronectin is adsorbed on the hydrophilic polymer layer. Relates to the device.

前記親水性ポリマー層は、下記式(I)で表されるポリマー及びポリ(メタ)アクリロイルモルホリンからなる群より選択される少なくとも1種の親水性ポリマーで形成されていることが好ましい。

Figure 0006485783
(式中、Rは水素原子又はメチル基、Rはアルキル基を表す。mは1〜5、nは繰り返し数を表す。) The hydrophilic polymer layer is preferably formed of at least one hydrophilic polymer selected from the group consisting of a polymer represented by the following formula (I) and poly (meth) acryloylmorpholine.
Figure 0006485783
(In the formula, R 1 represents a hydrogen atom or a methyl group, R 2 represents an alkyl group, m represents 1 to 5, and n represents a repeating number.)

前記親水性ポリマー層は、下記式(I−1)で表される化合物及び(メタ)アクリロイルモルホリンからなる群より選択される少なくとも1種の親水性モノマーと、他のモノマーとの共重合体で形成されていることが好ましい。

Figure 0006485783
(式中、R、R、mは前記と同様。) The hydrophilic polymer layer is a copolymer of at least one hydrophilic monomer selected from the group consisting of a compound represented by the following formula (I-1) and (meth) acryloylmorpholine and another monomer. Preferably it is formed.
Figure 0006485783
(Wherein R 1 , R 2 and m are the same as above)

前記医療用検査装置は、更に、フィブリノーゲンが吸着された部品を有することが好ましい。 It is preferable that the medical examination apparatus further includes a part on which fibrinogen is adsorbed.

本発明はまた、前述の医療用検査装置を用いて、血液又は体液中の細胞を調べる細胞検査方法に関する。
前記細胞検査方法は、医療用検査装置に導入する前に、血液又は体液をフィブリノーゲンが吸着された部品に接触させることが好ましい。
前記フィブリノーゲンが吸着された部品は、採血用注射器、採血管又は遠心分離管であることが好ましい。
前記細胞検査方法は、医療用検査装置に導入する前に、血液又は体液に遠心分離を施して上澄み及び/又は沈みを除去するものであることが好ましい。
The present invention also relates to a cytological examination method for examining cells in blood or body fluid using the medical examination apparatus described above.
In the cell inspection method, it is preferable that blood or body fluid is brought into contact with a part to which fibrinogen is adsorbed before being introduced into a medical inspection apparatus.
The part on which the fibrinogen is adsorbed is preferably a blood collection syringe, a blood collection tube or a centrifuge tube.
The cell inspection method is preferably a method in which the blood and body fluid are subjected to centrifugation to remove the supernatant and / or sediment before being introduced into the medical inspection apparatus.

本発明によれば、ウェル部を有する医療用検査装置であって、前記ウェル部の内面の少なくとも一部に親水性ポリマー層が形成され、かつ前記親水性ポリマー層にフィブロネクチンが吸着されている医療用検査装置であるため、EpCAMを発現していないがん細胞も含め、多くのがん細胞を捕捉できる。そのため、例えば、血液・体液中からがん細胞等の特定細胞を充分に捕捉でき、また、同時に他のタンパク質や細胞の粘着・接着も抑制できる。従って、がん細胞等を選択的に捕捉することが可能となる。 According to the present invention, there is provided a medical examination apparatus having a well part, wherein a hydrophilic polymer layer is formed on at least a part of the inner surface of the well part, and fibronectin is adsorbed on the hydrophilic polymer layer. Since it is an inspection apparatus, many cancer cells can be captured, including cancer cells that do not express EpCAM. Therefore, for example, specific cells such as cancer cells can be sufficiently captured from blood and body fluids, and adhesion and adhesion of other proteins and cells can be suppressed at the same time. Therefore, it becomes possible to selectively capture cancer cells and the like.

内面にフィブロネクチン吸着親水性ポリマー層が形成されたウェル部を有するマルチウェルプレート(医療用検査装置)の模式図の一例である。It is an example of the schematic diagram of the multiwell plate (medical test | inspection apparatus) which has a well part in which the fibronectin adsorption hydrophilic polymer layer was formed in the inner surface.

本発明は、ウェル部を有する医療用検査装置であって、前記ウェル部の内面の少なくとも一部に親水性ポリマー層が形成され、かつ前記親水性ポリマー層にフィブロネクチンが吸着されている医療用検査装置である。 The present invention is a medical examination apparatus having a well portion, wherein a hydrophilic polymer layer is formed on at least a part of the inner surface of the well portion, and fibronectin is adsorbed on the hydrophilic polymer layer. Device.

ウェル部の内面の少なくとも一部に親水性ポリマー層を形成するだけでなく、更にその親水性ポリマー層にフィブロネクチンも吸着させているので、親水性ポリマーのがん細胞等の特定細胞の接着(吸着)能力を非常に顕著に向上できる。従って、がん細胞等の特定細胞の捕捉性が大きく向上すると共に、血小板等の捕捉性が低下し、たんぱく質が多い状態では到底発揮し得ない特定細胞の選択的な捕捉効果を奏する。 In addition to forming a hydrophilic polymer layer on at least a part of the inner surface of the well part, fibronectin is also adsorbed to the hydrophilic polymer layer, so adhesion of specific cells such as cancer cells of the hydrophilic polymer (adsorption) ) Capability can be improved significantly. Therefore, the capturing ability of specific cells such as cancer cells is greatly improved, the capturing ability of platelets and the like is lowered, and there is a selective capturing effect of specific cells that can hardly be exhibited in a state where there are many proteins.

具体的に説明すると、血中循環腫瘍細胞(数個〜数百個/血液1mL)等の体液中にでてきた腫瘍細胞(がん細胞等)は、非常に数が少なく、検査に供するには、採取した体液中に存在する腫瘍細胞をできる限り多く捕捉することが重要である。本発明では、親水性ポリマー層に加え、腫瘍細胞の接着(吸着)を促進するフィブロネクチンを該親水性ポリマー層の表面に更に吸着させているため、これに血液等の体液を接触させることで、体液中の腫瘍細胞等が親水性ポリマー層に、より多く吸着・接着される。そして、吸着された腫瘍細胞等の特定細胞の数を測定することで、血液や体液中の特定細胞数が判り、がん治療効果の確認等を期待できる。また、捕捉した特定細胞を培養し、その培養した細胞で抗がん剤等の効き目を確認することで、抗がん剤等の投与前に、体の外で、抗がん剤等の効き目を確認できると同時に、抗がん剤等の選定にも役立つ。 More specifically, tumor cells (cancer cells, etc.) that have appeared in body fluids such as circulating tumor cells in the blood (several to several hundreds / ml of blood 1 mL) are very few and are used for examination. It is important to capture as many tumor cells as possible in the collected body fluid. In the present invention, in addition to the hydrophilic polymer layer, fibronectin that promotes adhesion (adsorption) of tumor cells is further adsorbed on the surface of the hydrophilic polymer layer, so that a body fluid such as blood is brought into contact therewith, More tumor cells and the like in the body fluid are adsorbed and adhered to the hydrophilic polymer layer. Then, by measuring the number of specific cells such as adsorbed tumor cells, the number of specific cells in blood or body fluid can be determined, and confirmation of cancer treatment effects can be expected. In addition, by culturing the captured specific cells and confirming the efficacy of the anticancer agent etc. in the cultured cells, before the administration of the anticancer agent etc., the efficacy of the anticancer agent etc. outside the body. Can also be used to select anticancer drugs.

以下、本発明の好ましい実施形態の一例を、図を用いて説明する。
図1(a)、(b)の医療用検査装置1(マルチウェルプレート1)は、がん細胞等の特定細胞を捕捉する目的で使用される装置で、いわゆるマトリクス状にウェル11が配置されたマルチウェルプレート1である。マルチウェルプレート1は、円形に開口された複数のウェル11を有している。ウェル11は、血液、体液等注入する凹部であり、注入した血液や体液の特定細胞の有無の確認、特定細胞数の計測、特定細胞の培養、薬の効き目の確認・選定を実施できる。
Hereinafter, an example of a preferred embodiment of the present invention will be described with reference to the drawings.
A medical examination apparatus 1 (multiwell plate 1) shown in FIGS. 1A and 1B is an apparatus used for capturing specific cells such as cancer cells. Wells 11 are arranged in a so-called matrix. Multiwell plate 1. The multiwell plate 1 has a plurality of wells 11 opened in a circular shape. The well 11 is a recess for injecting blood, body fluid, and the like, and can confirm the presence or absence of specific cells in the injected blood or body fluid, measure the number of specific cells, culture specific cells, and confirm and select the effectiveness of drugs.

図1(a)、(b)では、一例として、4行6列の24個のウェル11を有する24ウェルプレートを示しているが、マルチウェルプレート1は、ウェル11を少なくとも2つ以上有していれば良く、ウェル11の個数は任意である。24ウェルプレートの他には、ウェル11が、6個、96個、384個等の汎用マルチウェルプレートでも良い。
尚、ウェル11は、シングルウェル2(医療用検査装置2)でもよい(図1(c))。
FIGS. 1A and 1B show a 24-well plate having 24 wells 11 in 4 rows and 6 columns as an example, but the multiwell plate 1 has at least two wells 11 or more. The number of wells 11 is arbitrary. In addition to the 24-well plate, a general-purpose multi-well plate having six, 96, 384 wells 11 may be used.
The well 11 may be a single well 2 (medical examination apparatus 2) (FIG. 1C).

マルチウェルプレート1、シングルウェル2の構成材料としては、細胞検査時の観察で透明性が高いものがよく、ポリアクリル酸メチル、ポリメタクリル酸メチル、ポリアクリル酸、ポリメタクリル酸等のアクリル樹脂(ポリアクリル樹脂)、シクロオレフィン樹脂(ポリシクロオレフィン)、カーボネート樹脂(ポリカーボネート)、スチレン樹脂(ポリスチレン)、ポリエチレンテレフタレート(PET)等のポリエステル樹脂、ポリジメチルシロキサン及びガラス(ホウけい酸ガラス、ソーダ石灰ガラス等)等が挙げられる。親水性ポリマーのコーティングには、構成材料は親水性が高い方が良く、ポリアクリル樹脂やソーダ石灰ガラスが好ましい。 As a constituent material of the multi-well plate 1 and the single well 2, those having high transparency in observation at the time of cell examination are preferable, and acrylic resins such as polymethyl acrylate, polymethyl methacrylate, polyacrylic acid, and polymethacrylic acid ( Polyacrylic resin), cycloolefin resin (polycycloolefin), carbonate resin (polycarbonate), polyester resin such as styrene resin (polystyrene), polyethylene terephthalate (PET), polydimethylsiloxane and glass (borosilicate glass, soda lime glass) Etc.). For coating with a hydrophilic polymer, the constituent material should be highly hydrophilic, and polyacrylic resin or soda-lime glass is preferred.

ウェル11は非貫通孔であり、マルチウェルプレート1、シングルウェル2の表面に開口されている。ウェル11には、開口から、血液や体液が注入される。また、がん細胞等の特定細胞の存在を確認した場合、特定細胞を培養するための培養液を注入することも可能である。 The well 11 is a non-through hole, and is opened on the surfaces of the multiwell plate 1 and the single well 2. Blood and body fluid are injected into the well 11 from the opening. Further, when the presence of specific cells such as cancer cells is confirmed, it is possible to inject a culture solution for culturing the specific cells.

ウェル11の開口の直径R、深さDは、特に限定されず、通常のマルチウェルプレート1のR、Dを採用できる。図1では、マルチウェルプレート1、シングルウェル2の表面及び裏面に対して、ウェル11の内側面が略垂直であるが、ウェル11は、内側面が傾斜し、開口から底面にかけて窄まる形状でも良い。また、内側面が傾斜し、開口から底面にかけて拡がる形状でも良い。 The diameter R and depth D of the opening of the well 11 are not particularly limited, and R and D of the normal multiwell plate 1 can be adopted. In FIG. 1, the inner surface of the well 11 is substantially perpendicular to the front and back surfaces of the multiwell plate 1 and the single well 2, but the well 11 may have a shape in which the inner surface is inclined and narrows from the opening to the bottom surface. good. Moreover, the shape which an inner side surface inclines and expands from an opening to a bottom face may be sufficient.

図1では、ウェル11は円形に開口しているが、ウェル11の開口形状は任意であり、四角形等、任意の形状に開口したものでもよい。 In FIG. 1, the well 11 is opened in a circular shape, but the opening shape of the well 11 is arbitrary, and may be opened in an arbitrary shape such as a quadrangle.

マルチウェルプレート1は、複数のウェル11が分離可能なものを好適に使用できる。複数のウェルを有する場合、特定細胞数計測用ウェルと、特定細胞培養用ウェルとに分離使用でき、例えば、計測用ウェルでがん細胞の存在の有無を確認した上で、存在が確認された場合に培養用ウェルでがん細胞を培養し、その細胞で薬の効き目を確認できる。 As the multi-well plate 1, a plate in which a plurality of wells 11 can be separated can be suitably used. When there are multiple wells, it can be used separately for specific cell count measurement wells and specific cell culture wells. For example, the presence of cancer cells was confirmed after confirming the presence or absence of cancer cells in the measurement wells. In some cases, cancer cells are cultured in a culture well, and the effectiveness of the drug can be confirmed with the cells.

マルチウェルプレート1(医療用検査装置1)、シングルウェル2(医療用検査装置2)において、ウェル11の内側面は、少なくとも一部に親水性ポリマー層が形成され、かつ、該親水性ポリマー層にフィブロネクチンが吸着されている。図1は、ウェルの底面及び側面の一部に親水性ポリマー層21が形成され、更に該親水性ポリマー層21にフィブロネクチン31を吸着させている例を示している。 In the multiwell plate 1 (medical examination apparatus 1) and single well 2 (medical examination apparatus 2), a hydrophilic polymer layer is formed on at least a part of the inner surface of the well 11, and the hydrophilic polymer layer Has adsorbed fibronectin. FIG. 1 shows an example in which a hydrophilic polymer layer 21 is formed on a part of the bottom and side surfaces of a well, and fibronectin 31 is further adsorbed on the hydrophilic polymer layer 21.

ウェル11内に、血液や体液を導入すると、これらに含まれるがん細胞等の特定細胞は、フィブロネクチン31を吸着させた親水性ポリマー層21に吸着されると共に、血小板、赤血球等の吸着が抑制される。そのため、血液や体液の導入後に所定時間保持し、次いで、洗浄することで、特定細胞を親水性ポリマー層21に吸着できる。そして、吸着された特定細胞の数を測定することで、血液や体液中のがん細胞数が判り、がん治療効果の確認等が期待される。 When blood or body fluid is introduced into the well 11, specific cells such as cancer cells contained therein are adsorbed to the hydrophilic polymer layer 21 to which fibronectin 31 is adsorbed, and adsorption of platelets, erythrocytes and the like is suppressed. Is done. Therefore, specific cells can be adsorbed to the hydrophilic polymer layer 21 by holding for a predetermined time after introduction of blood or body fluid and then washing. Then, by measuring the number of adsorbed specific cells, the number of cancer cells in blood or body fluid can be determined, and confirmation of cancer treatment effects and the like are expected.

親水性ポリマー層21(親水性ポリマーにより形成される層)の膜厚は、好ましくは2〜200nm、より好ましくは20〜180nmである。上記範囲内に調整することで、良好なタンパク質や細胞に対する低吸着性、がん細胞に対する選択的吸着性・接着性が得られる。 The film thickness of the hydrophilic polymer layer 21 (layer formed of a hydrophilic polymer) is preferably 2 to 200 nm, more preferably 20 to 180 nm. By adjusting within the above-mentioned range, it is possible to obtain good protein and low adsorptivity to cells and selective adsorptivity and adhesion to cancer cells.

親水性ポリマーは、親水性を有するものを適宜選択できる。例えば、1種又は2種以上の親水性モノマーの単独重合体及び共重合体、1種又は2種以上の親水性モノマーと他のモノマーとの共重合体等が挙げられる。前記単独重合体、共重合体としては、ポリアクリル酸、ポリアクリル酸エステル、ポリメタクリル酸、ポリメタクリル酸エステル、ポリアクリロイルモルホリン、ポリメタクリロイルモルホリン、ポリアクリルアミド、ポリメタクリルアミド等が挙げられる。 As the hydrophilic polymer, a hydrophilic polymer can be appropriately selected. Examples thereof include homopolymers and copolymers of one or more hydrophilic monomers, copolymers of one or more hydrophilic monomers and other monomers, and the like. Examples of the homopolymer and copolymer include polyacrylic acid, polyacrylic acid ester, polymethacrylic acid, polymethacrylic acid ester, polyacryloylmorpholine, polymethacryloylmorpholine, polyacrylamide, and polymethacrylamide.

親水性モノマーは、親水性基を有する各種モノマーを使用できる。親水性基は、例えば、アミド基、硫酸基、スルホン酸基、カルボン酸基、水酸基、アミノ基、アミド基、オキシエチレン基等、公知の親水性基が挙げられる。 As the hydrophilic monomer, various monomers having a hydrophilic group can be used. Examples of the hydrophilic group include known hydrophilic groups such as an amide group, a sulfuric acid group, a sulfonic acid group, a carboxylic acid group, a hydroxyl group, an amino group, an amide group, and an oxyethylene group.

親水性モノマーの具体例としては、(メタ)アクリル酸、(メタ)アクリル酸エステル、(メトキシエチル(メタ)アクリレート等のアルコキシアルキル(メタ)アクリレート、ヒドロキシエチル(メタ)アクリレート等のヒドロキシアルキル(メタ)アクリレート)、(メタ)アクリルアミド、環状基を有する(メタ)アクリルアミド誘導体((メタ)アクリロイルモルホリン等)、などが挙げられる。 Specific examples of the hydrophilic monomer include (meth) acrylic acid, (meth) acrylic acid ester, alkoxyalkyl (meth) acrylate such as (methoxyethyl (meth) acrylate), and hydroxyalkyl (meth) acrylate such as hydroxyethyl (meth) acrylate. ) Acrylate), (meth) acrylamide, (meth) acrylamide derivatives having a cyclic group (such as (meth) acryloylmorpholine), and the like.

他のモノマーは、親水性ポリマーの作用効果を阻害しない範囲内で適宜選択すれば良い。例えば、スチレン等の芳香族モノマー、酢酸ビニル、温度応答性を付与できるN−イソプロピルアクリルアミドなどが挙げられる。 Other monomers may be appropriately selected within a range that does not inhibit the action and effect of the hydrophilic polymer. For example, aromatic monomers such as styrene, vinyl acetate, N-isopropylacrylamide capable of imparting temperature responsiveness, and the like can be given.

なかでも、親水性ポリマーとしては、下記式(I)で表されるポリマー及びポリ(メタ)アクリロイルモルホリンからなる群より選択される少なくとも1種が好ましい。

Figure 0006485783
(式中、Rは水素原子又はメチル基、Rはアルキル基を表す。mは1〜5、nは繰り返し数を表す。) Among them, the hydrophilic polymer is preferably at least one selected from the group consisting of a polymer represented by the following formula (I) and poly (meth) acryloylmorpholine.
Figure 0006485783
(In the formula, R 1 represents a hydrogen atom or a methyl group, R 2 represents an alkyl group, m represents 1 to 5, and n represents a repeating number.)

のアルキル基の炭素数は、1〜10が好ましく、1〜5がより好ましい。なかでも、Rは、メチル基又はエチル基が特に好ましい。mは、1〜3が好ましい。n(繰り返し単位数)は、15〜1000が好ましく、30〜500がより好ましい。 The carbon number of the alkyl group of R 2 is 1 to 10 preferably 1 to 5 is more preferable. Among these, R 2 is particularly preferably a methyl group or an ethyl group. m is preferably 1 to 3. n (the number of repeating units) is preferably 15 to 1,000, and more preferably 30 to 500.

また、親水性ポリマーとして、下記式(I−1)で表される化合物及び(メタ)アクリロイルモルホリンからなる群より選択される少なくとも1種の親水性モノマーと、他のモノマーとの共重合体も好適に使用できる。

Figure 0006485783
(式中、R、R、mは前記と同様。) Further, as a hydrophilic polymer, a copolymer of at least one hydrophilic monomer selected from the group consisting of a compound represented by the following formula (I-1) and (meth) acryloylmorpholine and another monomer is also used. It can be used suitably.
Figure 0006485783
(Wherein R 1 , R 2 and m are the same as above)

親水性ポリマーの重量平均分子量(Mw)は、がん細胞に対する選択的吸着性・接着性の観点から、好ましくは4000〜150000、より好ましくは5000〜100000、更に好ましくは8000〜50000である。なお、本明細書において、Mwは、ゲルパーミエーションクロマトグラフィー(GPC)(東ソー(株)製GPC−8000シリーズ、検出器:示差屈折計、カラム:東ソー(株)製のTSKGEL SUPERMALTPORE HZ−M)による測定値を基に標準ポリスチレン換算により求めることができる。 The weight average molecular weight (Mw) of the hydrophilic polymer is preferably 4,000 to 150,000, more preferably 5,000 to 100,000, and still more preferably 8,000 to 50,000 from the viewpoint of selective adsorptivity and adhesion to cancer cells. In this specification, Mw is gel permeation chromatography (GPC) (GPC-8000 series, manufactured by Tosoh Corp., detector: differential refractometer, column: TSKGEL SUPERMALTPORE HZ-M manufactured by Tosoh Corp.) Can be determined by standard polystyrene conversion based on the measured value of

親水性ポリマー層21上にフィブロネクチン31を吸着させるという点から、フィブロネクチン濃度を、好ましくは0.5〜500μg/ml、より好ましくは1〜250μg/mlに調整した溶液、分散液等を用いることが好適である。上記範囲内の濃度に調整することで、良好なタンパク質や細胞に対する低吸着性、がん細胞に対する選択的吸着性・接着性が得られる。 From the viewpoint of adsorbing fibronectin 31 on the hydrophilic polymer layer 21, it is preferable to use a solution, dispersion, or the like in which the fibronectin concentration is preferably adjusted to 0.5 to 500 μg / ml, more preferably 1 to 250 μg / ml. Is preferred. By adjusting to a concentration within the above-mentioned range, good adsorption to proteins and cells and selective adsorption / adhesion to cancer cells can be obtained.

本発明の医療用検査装置は、例えば、図1の内面にフィブロネクチン31を吸着させた親水性ポリマー層21が形成されているウェル11を備えたマルチウェルプレート1又はシングルウェル2、更に必要に応じて他の部材(部品)を付加することにより、製造できる。 The medical examination apparatus of the present invention includes, for example, a multiwell plate 1 or a single well 2 provided with a well 11 having a hydrophilic polymer layer 21 having fibronectin 31 adsorbed on the inner surface thereof in FIG. It can be manufactured by adding other members (parts).

具体的には、親水性ポリマー層21が形成されたマルチウェルプレート1、シングルウェル2の場合、(1)親水性ポリマーを各種溶剤に溶解・分散した親水性ポリマー溶液・分散液を、ウェル11の内部に注入し、所定時間保持する方法、(2)該親水性ポリマー溶液・分散液をウェル11の内面に塗工(噴霧)する方法、等、公知の手法により、ウェル11の内面の全部又は一部に親水性ポリマー溶液・分散液をコーティングすることで、親水性ポリマーにより形成されるポリマー層が形成されたマルチウェルプレート、シングルウェルを製造できる。 Specifically, in the case of the multiwell plate 1 and the single well 2 in which the hydrophilic polymer layer 21 is formed, (1) a hydrophilic polymer solution / dispersion solution obtained by dissolving and dispersing a hydrophilic polymer in various solvents is added to the well 11 The inner surface of the well 11 by a known method, such as a method of injecting into the inner surface of the well 11 and holding it for a predetermined time, or (2) a method of coating (spraying) the hydrophilic polymer solution / dispersion on the inner surface of the well 11 Alternatively, a multiwell plate or a single well in which a polymer layer formed of a hydrophilic polymer is formed can be produced by coating a hydrophilic polymer solution / dispersion on a part thereof.

溶剤、注入方法、塗工(噴霧)方法などは、従来公知の材料及び方法を適用できる。
(1)、(2)の保持時間は、ウェル11の大きさ、導入する液種、等により適宜設定すれば良いが、5分〜10時間が好ましく、10分〜5時間がより好ましく、15分〜2時間が更に好ましい。保持後、適宜、余分な親水性ポリマー溶液・分散液を排出し、乾燥してもよい。
Conventionally known materials and methods can be applied to the solvent, the injection method, the coating (spraying) method, and the like.
The retention time of (1) and (2) may be appropriately set depending on the size of the well 11, the type of liquid to be introduced, etc., but is preferably 5 minutes to 10 hours, more preferably 10 minutes to 5 hours, Minutes to 2 hours are more preferable. After the holding, the excess hydrophilic polymer solution / dispersion may be appropriately discharged and dried.

次いで、形成された親水性ポリマー層21にフィブロネクチン31を吸着させる方法は特に限定されず、公知の方法を適用できる。例えば、親水性ポリマー層21にフィブロネクチン31の緩衝溶液(リン酸緩衝生理食塩水PBS等)を公知の方法で接触させ、所定温度で所定時間放置し、必要に応じて洗浄する方法、等で吸着させることができる。温度、時間は適宜設定すればよく、例えば、10〜60℃、0.1〜10時間程度で実施できる。 Next, the method for adsorbing fibronectin 31 to the formed hydrophilic polymer layer 21 is not particularly limited, and a known method can be applied. For example, the hydrophilic polymer layer 21 is contacted with a buffer solution of fibronectin 31 (phosphate buffered saline PBS or the like) by a known method, left at a predetermined temperature for a predetermined time, and adsorbed by a method of washing as necessary. Can be made. What is necessary is just to set temperature and time suitably, for example, it can implement at 10-60 degreeC and about 0.1 to 10 hours.

そして、作製されたフィブロネクチン31が吸着された親水性ポリマー層21をウェル11の内面の一部に形成したマルチウェルプレート1、シングルウェル2に、必要に応じて他の部品を追加することで、医療用検査装置を製造できる。 Then, by adding other parts as necessary to the multiwell plate 1 and the single well 2 in which the hydrophilic polymer layer 21 to which the produced fibronectin 31 is adsorbed is formed on a part of the inner surface of the well 11, Medical inspection devices can be manufactured.

本発明では、他の部品として、フィブリノーゲンが吸着された部品を使用することが好ましい。検査用血液や体液を、血球細胞の接着に関係するフィブリノーゲンが吸着した部品に接触させることで、予め血球細胞数が減少し、がん細胞等の特定細胞の接着性・吸着性を向上できる。 In the present invention, it is preferable to use a component on which fibrinogen is adsorbed as another component. By bringing test blood or body fluid into contact with a part to which fibrinogen related to the adhesion of blood cells is adsorbed, the number of blood cells decreases in advance, and the adhesion / adsorption of specific cells such as cancer cells can be improved.

本発明の細胞検査方法は、前述の医療用検査装置を用いて、血液又は体液中の細胞を調べる細胞検査方法である。前記のとおり、本発明の医療用検査装置は、がん細胞等の捕捉性が向上すると共に、血小板等の捕捉性が低下し、がん細胞等の選択的な捕捉効果が得られるため、これを用いて血液又は体液中の細胞を調べることで、前述のがん治療効果の確認、体の外での抗がん剤等の効き目の確認、抗がん剤等の選定、等が期待できる。 The cell inspection method of the present invention is a cell inspection method for examining cells in blood or body fluid using the above-described medical inspection apparatus. As described above, the medical examination apparatus according to the present invention improves the capturing ability of cancer cells and the like, decreases the capturing ability of platelets and the like, and obtains a selective capturing effect of cancer cells and the like. By examining cells in blood or body fluids using, you can expect the confirmation of the above-mentioned cancer treatment effect, confirmation of the efficacy of anticancer agents outside the body, selection of anticancer agents, etc. .

前記細胞検査方法は、予め血球細胞数を減少させ、がん細胞等の接着性・吸着性を向上できる観点から、医療用検査装置に導入(注入、滴下等)する前に、血液又は体液をフィブリノーゲンが吸着された部品に接触させる方法が好ましい。例えば、フィブリノーゲンが吸着された部品として、採血用注射器、採血管又は遠心分離管を用いることで、前記効果が顕著に得られる。 From the viewpoint of reducing the number of blood cells and improving the adhesion / adsorption properties of cancer cells and the like, the cell inspection method may be performed by introducing blood or body fluid before introduction (injection, dropping, etc.) into a medical examination apparatus. A method of contacting a part on which fibrinogen is adsorbed is preferable. For example, by using a blood collection syringe, a blood collection tube, or a centrifuge tube as a part to which fibrinogen is adsorbed, the above-described effect can be obtained remarkably.

また、前記細胞検査方法は、予め血球細胞数を減少させ、がん細胞等の接着性・吸着性を向上できる観点から、医療用検査装置に導入(注入、滴下等)する前に、血液又は体液に遠心分離を施して上澄み及び/又は沈み(沈降物)を除去する方法が好ましい。 In addition, from the viewpoint of reducing the number of blood cells and improving the adhesion / adsorption properties of cancer cells and the like, the cell inspection method may be performed before introducing (injection, dripping, etc.) into a medical inspection apparatus. A method of centrifuging body fluid to remove supernatant and / or sediment (sediment) is preferred.

以下、実施例に基づいて本発明を具体的に説明するが、本発明はこれらのみに限定されるものではない。 EXAMPLES Hereinafter, although this invention is demonstrated concretely based on an Example, this invention is not limited only to these.

(実施例1)
AIBN(アゾビスイソブチロニトリル)を用いて、2−メトキシエチルアクリレートを80℃で6時間熱重合し、ポリ2−メトキシエチルアクリレートを作製した(分子量Mn:約15000、Mw:約50000)。そして、得られたポリ2−メトキシエチルアクリレートの2.5W/V%メタノール溶液を作製した。
市販PMMA製プレート内に、作製したポリ2−メトキシエチルアクリレート溶液(2.5W/V%)を注入し、30分室温放置した後、液をピペットで吸出し、乾燥することで、親水性ポリマー層を作製した。
更に、ポリ2−メトキシエチルアクリレートがコーティングされた部分(親水性ポリマー層)にフィブロネクチンを吸着させた。具体的にはフィブロネクチンのPBS溶液(リン酸緩衝生理食塩水)1μl/mlを作製し、40℃1時間放置した後、PBS溶液で洗浄することで、図1のフィブロネクチン吸着親水性ポリマー層が形成されたマルチウェルプレートを有する検査装置を作製した。
Example 1
Using AIBN (azobisisobutyronitrile), 2-methoxyethyl acrylate was thermally polymerized at 80 ° C. for 6 hours to prepare poly-2-methoxyethyl acrylate (molecular weight Mn: about 15000, Mw: about 50000). And the 2.5 W / V% methanol solution of the obtained poly 2-methoxyethyl acrylate was produced.
Inject the prepared poly-2-methoxyethyl acrylate solution (2.5 W / V%) into a commercially available PMMA plate, leave it at room temperature for 30 minutes, and then suck out the solution with a pipette and dry it. Was made.
Furthermore, fibronectin was adsorbed on the portion (hydrophilic polymer layer) coated with poly-2-methoxyethyl acrylate. Specifically, 1 μl / ml of fibronectin in PBS (phosphate buffered saline) is prepared, left at 40 ° C. for 1 hour, and washed with PBS solution to form the fibronectin-adsorbing hydrophilic polymer layer in FIG. An inspection apparatus having a prepared multi-well plate was produced.

(実施例2)
PBS溶液を10μl/mlに変更した以外は、実施例1と同様に検査装置を作製した。
(Example 2)
An inspection apparatus was prepared in the same manner as in Example 1 except that the PBS solution was changed to 10 μl / ml.

(実施例3)
PBS溶液を100μl/mlに変更した以外は、実施例1と同様に検査装置を作製した。
(Example 3)
An inspection device was prepared in the same manner as in Example 1 except that the PBS solution was changed to 100 μl / ml.

(実施例4)
別に、ピペットの内面をフィブリノーゲン10μl/ml溶液でコーティングし、PBS溶液で洗浄した後、十分水分を切った状態のピペット(フィブリノーゲンが吸着された採血管)を作製した以外は、実施例2と同様に検査装置を作製した。
Example 4
Separately, the inner surface of the pipette was coated with a 10 μl / ml solution of fibrinogen, washed with a PBS solution, and then a pipette (a blood collection tube to which fibrinogen was adsorbed) that had been sufficiently drained was prepared. An inspection device was prepared.

(実施例5)
PBS溶液を200μl/mlに変更した以外は、実施例1と同様に検査装置を作製した。
(Example 5)
An inspection device was prepared in the same manner as in Example 1 except that the PBS solution was changed to 200 μl / ml.

(比較例1)
ポリ2−メトキシエチルアクリレート層のみを形成した以外は、実施例1と同様に検査装置を作製した。
(Comparative Example 1)
An inspection apparatus was produced in the same manner as in Example 1 except that only the poly-2-methoxyethyl acrylate layer was formed.

実施例、比較例で作製した医療用検査装置を以下の方法で評価した。なお、実施例4では、予め、作製したピペットで血液を吸い上げ、10分保持した後、ウェルに注入した以外は、同様に評価した。 The medical examination apparatus produced by the Example and the comparative example was evaluated with the following method. In Example 4, the evaluation was made in the same manner except that blood was sucked with a prepared pipette in advance and held for 10 minutes and then injected into the well.

〔親水性ポリマー層(コーティング層)の膜厚〕
ウェル内面の親水性ポリマー層の膜厚は、TEMを使用し、加速電圧15kV、1000倍で測定(撮影)した。
[Film thickness of hydrophilic polymer layer (coating layer)]
The film thickness of the hydrophilic polymer layer on the inner surface of the well was measured (photographed) using TEM at an acceleration voltage of 15 kV and 1000 times.

〔血小板吸着量〕
ウェルに、血漿に血小板を混合し、血小板濃度(播種密度)を4×10cells/cmに調整した液を注入し、37℃で1時間静置した。内部をリン酸緩衝生理食塩水で洗浄した後、1%グルタルアルデヒドで固定した(37℃で2時間放置)。その後、再度リン酸緩衝生理食塩水及び蒸留水で洗浄した。
このサンプルをSEMで観察し、吸着した血小板の数を数えた。なお、比較例1の数を1.0として、相対値で比較した。
[Platelet adsorption]
A well was mixed with plasma and mixed with platelets (seed density) adjusted to 4 × 10 7 cells / cm 2 and allowed to stand at 37 ° C. for 1 hour. The interior was washed with phosphate buffered saline and fixed with 1% glutaraldehyde (left at 37 ° C. for 2 hours). Then, it was washed again with phosphate buffered saline and distilled water.
This sample was observed by SEM, and the number of adsorbed platelets was counted. In addition, the number of the comparative example 1 was set to 1.0 and it compared by the relative value.

〔がん細胞数の計測〕
線維肉腫(HT−1080)を剥離液を用いて懸濁させ、一部をPBS溶液に混濁させて、細胞数を血球計測管でカウントした後、この値を用いて、血液に線維肉腫(HT−1080)の入った剥離液を混濁させた。このとき、播種密度(濃度)が2850cells/cmに計算上なるように血液を混濁させた。
この血液を用いて、ウェルに1mlずつ注入し、37℃で1時間接着させた。その後、PBS溶液で未接着の細胞を洗浄した。次いで、免疫染色を行い、蛍光顕微鏡で接着したがん細胞数をカウントした。なお、比較例1の接着数を1.0として、相対値で比較した。
[Counting the number of cancer cells]
Fibrosarcoma (HT-1080) is suspended using a stripping solution, a part is made turbid in PBS solution, the number of cells is counted with a hemocytometer, and this value is used to add fibrosarcoma (HT The stripping solution containing -1080) was made turbid. At this time, the blood was turbid so that the seeding density (concentration) was calculated to 2850 cells / cm 2 .
Using this blood, 1 ml was injected into each well and allowed to adhere at 37 ° C. for 1 hour. Thereafter, unadhered cells were washed with a PBS solution. Subsequently, immunostaining was performed, and the number of cancer cells adhered with a fluorescence microscope was counted. In addition, the number of adhesion of the comparative example 1 was set to 1.0, and it compared by the relative value.

〔全血にがん細胞を添加したスパイク血試験〕
染色をしたヒト結腸癌由来上皮細胞(HT−29)を全血に100個/血液1mLになる様に懸濁させた(スパイク血)。これに等量の液体培地を入れて希釈した(希釈スパイク血)。次に、15mLの遠心分離管に、単核球細胞液(LymphoPrep:密度1.077±0.001g/mL)を入れて、その上に上記希釈スパイク血を入れて、800g20分の条件で遠心分離を行った。そして単核球層を分離した。分離した単核球層にリン酸バッファー(PBS)溶液を添加して、遠心分離を再度行い、濃縮を行った。遠心分離後の最下層にできた塊をFBS(ウシ胎児血清)10%添加液体培地(最初の全血量と同じ液量)で懸濁させた。この懸濁液を用いて、ウェルに1mlずつ注入し、37℃で1時間接着させた。その後、PBS溶液で未接着の細胞を洗浄した。次いで、蛍光顕微鏡で接着したがん細胞数をカウントした。なお、比較例1の接着数を1.00として、相対値で比較した。
[Spike blood test with cancer cells added to whole blood]
Stained human colon cancer-derived epithelial cells (HT-29) were suspended in whole blood at 100 cells / ml of blood (spike blood). This was diluted with an equal volume of liquid medium (diluted spike blood). Next, a mononuclear cell solution (LymphoPrep: density 1.077 ± 0.001 g / mL) is put into a 15 mL centrifuge tube, and the above-described diluted spiked blood is added thereto, followed by centrifugation at 800 g for 20 minutes. Separation was performed. And the mononuclear cell layer was separated. A phosphate buffer (PBS) solution was added to the separated mononuclear cell layer, and centrifugation was performed again for concentration. The clot formed in the lowermost layer after centrifugation was suspended in a liquid medium supplemented with 10% FBS (fetal bovine serum) (the same volume as the initial whole blood volume). Using this suspension, 1 ml was injected into each well and allowed to adhere at 37 ° C. for 1 hour. Thereafter, unadhered cells were washed with a PBS solution. Subsequently, the number of cancer cells adhered with a fluorescence microscope was counted. In addition, the adhesion number of the comparative example 1 was set to 1.00, and it compared by the relative value.

Figure 0006485783
Figure 0006485783

Figure 0006485783
Figure 0006485783

フィブロネクチンを吸着させた親水性ポリマー層を形成した実施例1〜3は、親水性ポリマー層のみを形成した比較例1に比べ、がん細胞の接着量が大幅に向上した。これは、ポリ2−メトキシエチルアクリレート層上に、がん細胞の接着に関連するたんぱく質のフィブロネクチンを吸着させていたため、がん細胞が優先的に接着したものと推察された。 In Examples 1 to 3 in which the hydrophilic polymer layer to which fibronectin was adsorbed was formed, the adhesion amount of cancer cells was significantly improved as compared with Comparative Example 1 in which only the hydrophilic polymer layer was formed. This was presumed that cancer cells preferentially adhered because the protein fibronectin related to cancer cell adhesion was adsorbed onto the poly-2-methoxyethyl acrylate layer.

予め、血液を、フィブリノーゲンを表面に吸着させた容器(ピペット内面)に接触させた実施例4は、更に接着量が向上した。これは、ウェルへの滴下前に、予め、容器内面に血球細胞の接着に関係するフィブリノーゲンが吸着したピペットに血液を注入したため、血球細胞数が減り、がん細胞の接着性が更に向上したものと推察された。 In Example 4 in which blood was previously brought into contact with a container (inner pipette surface) on which fibrinogen was adsorbed on the surface, the amount of adhesion was further improved. This is because blood was injected into a pipette that had previously adsorbed fibrinogen related to the adhesion of blood cells to the inner surface of the container before dropping into the well, so the number of blood cells was reduced and the adhesion of cancer cells was further improved It was guessed.

また、実施例は、血小板の吸着量が少ない一方で、がん細胞の接着量が多く、選択性(がん細胞接着量/血小板吸着量)も良好であった。 Further, in the Examples, while the amount of adsorbed platelets was small, the amount of cancer cells adhered was large, and the selectivity (cancer cell adhesion amount / platelet adsorbed amount) was also good.

表2によれば、表1でがん細胞の接着性が良好な実施例4、フィブロネクチン濃度を増加させた実施例5は、全血にがん細胞を添加したスパイク血試験でもがん細胞の接着性に優れていた。 According to Table 2, Example 4 in which the adhesion of cancer cells in Table 1 is good, and Example 5 in which the fibronectin concentration is increased are the same in the spike blood test in which cancer cells are added to whole blood. Excellent adhesion.

1 医療用検査装置(マルチウェルプレート)
2 医療用検査装置(シングルウェル)
11 ウェル
21 親水性ポリマー層
31 フィブロネクチン
1 Medical testing equipment (multiwell plate)
2 Medical testing equipment (single well)
11 Well 21 Hydrophilic polymer layer 31 Fibronectin

Claims (7)

ウェル部を有する医療用検査装置であって、
前記ウェル部の内面の少なくとも一部に親水性ポリマー層が形成され、かつ前記親水性ポリマー層にフィブロネクチンが吸着されており、
前記親水性ポリマー層は、下記式(I)で表されるポリマー及びポリ(メタ)アクリロイルモルホリンからなる群より選択される少なくとも1種の親水性ポリマーで形成されている医療用検査装置。
Figure 0006485783
(式中、Rは水素原子又はメチル基、Rはアルキル基を表す。mは1〜5、nは繰り返し数を表す。)
A medical examination apparatus having a well part,
A hydrophilic polymer layer is formed on at least a part of the inner surface of the well portion, and fibronectin is adsorbed on the hydrophilic polymer layer;
The hydrophilic polymer layer, the following formula (I) represented by polymers and poly (meth) acrylate of at least one hydrophilic polymer formed which do that physicians Ryoyo testing device is selected from the group consisting of acryloyl morpholine.
Figure 0006485783
(In the formula, R 1 represents a hydrogen atom or a methyl group, R 2 represents an alkyl group, m represents 1 to 5, and n represents a repeating number.)
ウェル部を有する医療用検査装置であって、
前記ウェル部の内面の少なくとも一部に親水性ポリマー層が形成され、かつ前記親水性ポリマー層にフィブロネクチンが吸着されており、
前記親水性ポリマー層は、下記式(I−1)で表される化合物及び(メタ)アクリロイルモルホリンからなる群より選択される少なくとも1種の親水性モノマーと、他のモノマーとの共重合体で形成されている医療用検査装置。
Figure 0006485783
(式中、R、R、mは前記と同様。)
A medical examination apparatus having a well part,
A hydrophilic polymer layer is formed on at least a part of the inner surface of the well portion, and fibronectin is adsorbed on the hydrophilic polymer layer;
The hydrophilic polymer layer is a copolymer of at least one hydrophilic monomer selected from the group consisting of a compound represented by the following formula (I-1) and (meth) acryloylmorpholine and another monomer. formed have that doctor Ryoyo inspection apparatus.
Figure 0006485783
(Wherein R 1 , R 2 and m are the same as above)
ウェル部を有する医療用検査装置であって、
前記ウェル部の内面の少なくとも一部に親水性ポリマー層が形成され、かつ前記親水性ポリマー層にフィブロネクチンが吸着されており、
更に、フィブリノーゲンが吸着された部品を有する医療用検査装置。
A medical examination apparatus having a well part,
A hydrophilic polymer layer is formed on at least a part of the inner surface of the well portion, and fibronectin is adsorbed on the hydrophilic polymer layer;
Further, that having a fibrinogen is adsorbed components Medical Ryoyo inspection apparatus.
請求項1〜のいずれかに記載の医療用検査装置を用いて、血液又は体液中の細胞を調べる細胞検査方法。 Using medical examination apparatus according to any one of claims 1 to 3 cell inspection method of examining cells of the blood or body fluid. 医療用検査装置に導入する前に、血液又は体液をフィブリノーゲンが吸着された部品に接触させる請求項記載の細胞検査方法。 The cell inspection method according to claim 4 , wherein blood or body fluid is brought into contact with a part on which fibrinogen is adsorbed before being introduced into the medical inspection apparatus. フィブリノーゲンが吸着された部品が採血用注射器、採血管又は遠心分離管である請求項記載の細胞検査方法。 6. The cytological test method according to claim 5 , wherein the part to which fibrinogen is adsorbed is a blood collection syringe, a blood collection tube or a centrifuge tube. 医療用検査装置に導入する前に、血液又は体液に遠心分離を施して上澄み及び/又は沈みを除去するものである請求項のいずれかに記載の細胞検査方法。 The cell inspection method according to any one of claims 4 to 6 , wherein the supernatant and / or sediment is removed by centrifuging blood or body fluid before introduction into the medical inspection apparatus.
JP2017144556A 2016-09-29 2017-07-26 Medical inspection apparatus and cell inspection method Active JP6485783B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/693,919 US10941374B2 (en) 2016-09-29 2017-09-01 Medical analysis device and cell analysis method
EP17189342.3A EP3301443B1 (en) 2016-09-29 2017-09-05 Medical analysis device and cell analysis method
CN201710826823.3A CN107884558B (en) 2016-09-29 2017-09-14 Medical analysis device and cell analysis method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191617 2016-09-29
JP2016191617 2016-09-29

Publications (2)

Publication Number Publication Date
JP2018059901A JP2018059901A (en) 2018-04-12
JP6485783B2 true JP6485783B2 (en) 2019-03-20

Family

ID=61909781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017144556A Active JP6485783B2 (en) 2016-09-29 2017-07-26 Medical inspection apparatus and cell inspection method

Country Status (1)

Country Link
JP (1) JP6485783B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6779483B2 (en) 2016-09-29 2020-11-04 住友ゴム工業株式会社 Medical testing equipment and cell testing method
JP7109719B2 (en) 2018-02-14 2022-08-01 住友ゴム工業株式会社 Specific cell capture method
CN111500441A (en) * 2019-01-24 2020-08-07 住友橡胶工业株式会社 Cell culture apparatus and cell culture method
US11614440B2 (en) 2019-01-24 2023-03-28 Sumitomo Rubber Industries, Ltd. Specific cell fractionating and capturing methods
JP6895662B2 (en) * 2019-01-24 2021-06-30 住友ゴム工業株式会社 Fractionation method and capture method of specific cells
JP6886668B2 (en) * 2019-04-23 2021-06-16 住友ゴム工業株式会社 Medical testing equipment and cell testing method
JP2021187907A (en) * 2020-05-27 2021-12-13 住友ゴム工業株式会社 Hydrophilic substrate and method for preparing hydrophilic substrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1315829B1 (en) * 2000-09-09 2010-07-28 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
WO2013134788A1 (en) * 2012-03-09 2013-09-12 Massachusetts Institute Of Technology Adhesion signatures
EP2948776B8 (en) * 2013-01-25 2020-02-26 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
KR102331655B1 (en) * 2013-11-19 2021-11-30 플라토드 Fluidic device for producing platelets
US11583860B2 (en) * 2014-12-22 2023-02-21 Ecole Polytechnique Federale De Lausanne (Epfl) Microstructured thin hydrogel films
JP2016131561A (en) * 2015-01-22 2016-07-25 国立大学法人山形大学 Method of recovering cells, and polymer used for the same

Also Published As

Publication number Publication date
JP2018059901A (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP6485783B2 (en) Medical inspection apparatus and cell inspection method
EP3301443B1 (en) Medical analysis device and cell analysis method
JP6518985B2 (en) Cancer cell capture method
JP7158671B2 (en) Specific cell capture method
JP7170254B2 (en) Specific cell capture method
JP2017203763A (en) Medical inspection device and cell inspection method
US20170320056A1 (en) Medical analysis device and cell analysis method
JP6779483B2 (en) Medical testing equipment and cell testing method
JP6895662B2 (en) Fractionation method and capture method of specific cells
JP7109719B2 (en) Specific cell capture method
JP6886667B2 (en) Cancer cell capture method
EP3686598B1 (en) Specific cell fractionating and capturing methods
JP7580076B2 (en) Cell culture device and cell culture method
JP2020115787A (en) Cell culture apparatus and cell culture method

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180730

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180730

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190208

R150 Certificate of patent or registration of utility model

Ref document number: 6485783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250